Dydrogesterone Raw Material Drug , Raw Hormone Powders CAS 152-62-5 CAS NO.152-62-5

product name: dydrogesterone
synonyms: dydrogesterone;(9β,10α)-pregna-4,6-diene-3,20-dione;10alpha-isopregnenone;10α-pregna-4,6-diene-3,20-dione;20-dione,(9-beta,10-alpha)-pregna-6-diene-3;20-dione,(9beta,10alpha)-pregna-6-diene-3;6-dehydro-9beta,10alpha-progesterone;6-dehydro-retroprogesteron
cas: 152-62-5
mf: c21h28o2
mw: 312.45
einecs: 205-806-8

density: 1.1g/cm3
melting point: 168-173ºc
boiling point: 462.8ºc at 760mmhg
flash point: 172.2ºc
refractive index: 1.556
vapor pressure: 9.55e-09mmhg at 25°c

description

dydrogesterone has selective progestational activity and does not inhibit ovulation. the greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. as a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.

application

1 . uses central stimulant, convulsant
2 . uses a synthetic progestin largely used in hormone therapy, on the central nervous system by studying two markers of the neuroendocrine function: the neurosteroid allopregnanolone and the opioid .beta.-endorphin. progestogen.

3 . dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. the molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.
4 . dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. this is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. the molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.